Citigroup Issues Positive Forecast for Veradermics (NYSE:MANE) Stock Price

Veradermics (NYSE:MANE) had its target price upped by equities research analysts at Citigroup from $160.00 to $175.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup‘s target price would suggest a potential upside of 17.67% from the company’s previous close.

Other equities analysts have also recently issued reports about the company. B. Riley Financial lifted their price objective on Veradermics from $170.00 to $204.00 and gave the stock a “buy” rating in a report on Thursday, October 22nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Veradermics in a report on Monday, October 19th. Needham & Company LLC raised their price target on Veradermics from $164.00 to $172.00 and gave the company a “buy” rating in a research report on Monday, October 19th. Leerink Partners lifted their price target on Veradermics from $135.00 to $150.00 and gave the stock an “outperform” rating in a research note on Monday. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Veradermics in a research report on Friday, August 21st. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $174.57.

Veradermics Price Performance

Shares of MANE stock traded up $4.76 during midday trading on Tuesday, reaching $148.72. 360,002 shares of the company traded hands, compared to its average volume of 640,036. The firm’s 50 day simple moving average is $118.66 and its two-hundred day simple moving average is $97.43. Veradermics has a 1-year low of $32.00 and a 1-year high of $152.82. The firm has a market cap of $6.21 billion and a PE ratio of -78.29.

Veradermics (NYSE:MANE) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.50) EPS for the quarter. As a group, research analysts anticipate that Veradermics will post -2.87 earnings per share for the current fiscal year.

Insider Buying and Selling at Veradermics

In related news, Director John Childs sold 100,000 shares of Veradermics stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $107.12, for a total transaction of $10,712,000.00. Following the completion of the transaction, the director directly owned 194,117 shares in the company, valued at $20,793,813.04. The trade was a 34.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Reid Alexander Waldman sold 67,500 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $107.86, for a total value of $7,280,550.00. Following the completion of the sale, the chief executive officer directly owned 170,824 shares in the company, valued at approximately $18,425,076.64. The trade was a 28.32% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 961,000 shares of company stock valued at $103,120,220.

Institutional Trading of Veradermics

A number of large investors have recently made changes to their positions in MANE. Montanova Capital LLC acquired a new position in Veradermics in the 2nd quarter valued at about $512,533,000. Bamco Inc. NY lifted its holdings in Veradermics by 284.8% in the 2nd quarter. Bamco Inc. NY now owns 229,581 shares of the company’s stock valued at $28,225,000 after purchasing an additional 169,913 shares in the last quarter. Seven Fleet Capital Management LP acquired a new stake in shares of Veradermics during the 2nd quarter worth about $9,835,000. Wellington Management Group LLP acquired a new stake in shares of Veradermics during the 2nd quarter worth about $8,425,000. Finally, Alps Advisors Inc. grew its holdings in shares of Veradermics by 31.2% during the third quarter. Alps Advisors Inc. now owns 55,356 shares of the company’s stock worth $6,711,000 after buying an additional 13,150 shares in the last quarter.

More Veradermics News

Here are the key news stories impacting Veradermics this week:

• Positive Sentiment: Veradermics reported positive 12-month results from Part B of Phase 3 Study 302 in men with pattern hair loss, including the highest hair-count result reported in its VDPHL01 Phase 3 program to date. The clinical progress may strengthen the candidate’s commercial prospects. Article: Veradermics Achieved the Highest VDPHL01 Reported Hair Count
• Positive Sentiment: Leerink Partners raised its price target from $135 to $150 and maintained an Outperform rating, signaling continued analyst optimism, though the revised target implies limited upside relative to the price cited in the report. Analyst rating information
• Neutral Sentiment: Veradermics reported a third-quarter 2026 loss of $0.50 per share. The available report does not provide an analyst-consensus comparison, making the earnings result’s surprise impact unclear. Article: Veradermics Reports Third Quarter 2026 Results

Veradermics Company Profile

Veradermics is a clinical-stage biopharmaceutical company focused on developing treatments for hair loss. Its lead candidate, VDPHL01, is an investigational oral formulation of minoxidil being studied for androgenetic alopecia, commonly known as male- or female-pattern hair loss. The company has described the treatment as designed for once-daily use. VDPHL01 remains under clinical investigation and is not an approved treatment. Veradermics is led by founder and Chief Executive Officer Reid Waldman, a physician specializing in dermatology.